Patents by Inventor William D. Bedzyk

William D. Bedzyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10088490
    Abstract: A method for determining an analyte in a sample suspected of containing the analyte comprises providing in combination a medium, the sample, and two or more different receptors. Each different receptor binds to at least two different epitopic sites. One of the epitopic sites is a common binding site and one of the epitopic sites is non-common binding site. The non-common epitopic sites are different for each different receptor. The receptors exhibit mono-molecular binding. The medium is incubated under conditions for binding of the receptors to the epitopic sites. The medium is examined for the presence and/or amount of complexes comprising the epitopic sites and the receptors. The presence and/or amount of the complexes indicate the presence and/or amount of the analyte in the sample.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: October 2, 2018
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Sandra A. Lewisch, Lynn M. Schiavoni, William D. Bedzyk
  • Patent number: 9815907
    Abstract: Antibodies are raised against compounds of Formula (I) where Z is an immunogenic carrier. These compounds are capable of binding specifically to corresponding antibodies. The antibodies are specific for epimers of vitamin D. Antibodies in accordance with the principles described herein may be employed to minimize or eliminate 3-epimer cross-reactivity in assays for non-epimeric forms of vitamin D analytes. Over-estimation of total non-epimeric vitamin D analyte caused by the cross-reactivity of 3-epimer vitamin D with an antibody for vitamin D analyte can be substantially avoided employing, as blocking agents, antibodies prepared against immunogens that are a compound of the Formula (I) wherein Z is an immunogenic carrier.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 14, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Manoj Sharma, Tatiana Mareeva, Yuriy Smirnov, William D. Bedzyk, Zhu Teng, Tie Quan Wei
  • Publication number: 20170121426
    Abstract: Antibodies are raised against compounds of Formula (I) where Z is an immunogenic carrier. These compounds are capable of binding specifically to corresponding antibodies. The antibodies are specific for epimers of vitamin D. Antibodies in accordance with the principles described herein may be employed to minimize or eliminate 3-epimer cross-reactivity in assays for non-epimeric forms of vitamin D analytes. Over-estimation of total non-epimeric vitamin D analyte caused by the cross-reactivity of 3-epimer vitamin D with an antibody for vitamin D analyte can be substantially avoided employing, as blocking agents, antibodies prepared against immunogens that are a compound of the Formula (I) wherein Z is an immunogenic carrier.
    Type: Application
    Filed: June 22, 2015
    Publication date: May 4, 2017
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Manoj Sharma, Tatiana Mareeva, Yuriy Smirnov, William D. Bedzyk, Zhu Teng, Tie Quan Wei
  • Publication number: 20120045847
    Abstract: A method for determining an analyte in a sample suspected of containing the analyte comprises providing in combination a medium, the sample, and two or more different receptors. Each different receptor binds to at least two different epitopic sites. One of the epitopic sites is a common binding site and one of the epitopic sites is non-common binding site. The non-common epitopic sites are different for each different receptor. The receptors exhibit mono-molecular binding. The medium is incubated under conditions for binding of the receptors to the epitopic sites. The medium is examined for the presence and/or amount of complexes comprising the epitopic sites and the receptors. The presence and/or amount of the complexes indicate the presence and/or amount of the analyte in the sample.
    Type: Application
    Filed: August 20, 2010
    Publication date: February 23, 2012
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Sandra A. Lewisch, Lynn M. Schiavoni, William D. Bedzyk
  • Patent number: 7858399
    Abstract: The present invention relates to immobilized procainamide analogs, as well as to a method of making immobilized procainamide analogs. These immobilized analogs are prepared by activating the carboxyl group on a substituted p-benzoic acid derivative toward nucleophilic attack; reacting the activated benzoic acid derivative with a polyamine to produce the benzoic acid derivative of Formula 3: and binding the benzoic acid derivative of Formula 3 to a latex polymer having functional groups that react with aliphatic amino groups. A method of conducting an immunoassay using the immobilized procainamide analog Formula 3 is described, comprising the steps of preparing a solution comprising said immobilized procainamide analog; adding a sample suspected of containing procainamide to said solution; adding an anti-procainamide antibody to said solution and observing the rate of increase in solution turbidity following antibody addition.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 28, 2010
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Victor P. Chu, Zhu Teng, Steve P. A. Goss, Ronald A. Edwards, Kelle M. Garvey, Timothy J. Gorzynski, William D. Bedzyk
  • Patent number: 7279340
    Abstract: The present invention relates to immobilized procainamide analogs, as well as to a method of making immobilized procainamide analogs. These immobilized analogs are prepared by activating the carboxyl group on a substituted p-benzoic acid derivative toward nucleophilic attack; reacting the activated benzoic acid derivative with a polyamine to produce the benzoic acid derivative of Formula 3: and binding the benzoic acid derivative of Formula 3 to a latex polymer having functional groups that react with aliphatic amino groups. A method of conducting an immunoassay using the immobilized procainamide analog Formula 3 is described, comprising the steps of preparing a solution comprising said immobilized procainamide analog; adding a sample suspected of containing procainamide to said solution; adding an anti-procainamide antibody to said solution and observing the rate of increase in solution turbidity following antibody addition.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: October 9, 2007
    Assignee: Dade Behring Inc.
    Inventors: Victor P. Chu, Zhu Teng, Steve P. A. Goss, Ronald L. Edwards, Kelle M. Garvey, Timothy J. Gorzynski, William D. Bedzyk